Guerbet Reports Nearly Stable Revenue for First Half of 2026
Medical imaging specialist Guerbet published its first-half 2026 financial results, showing revenue nearly stable on a comparable basis despite currency headwinds. The company experienced mixed regional performance, with a strong recovery in the Americas.
Villepinte, France – Guerbet, a global specialist in contrast agents and solutions for medical imaging, announced on July 23, 2026, that its revenue for the first half of 2026 reached €379.2 million. The reported revenue showed a 2.2% decrease compared to the first half of 2025, which included an unfavorable foreign exchange effect of €8.0 million.
On a constant exchange rate (CER) and like-for-like basis, the Group's revenue remained nearly stable, falling by only 0.1%. The company noted that this stability was supported by 2.6% growth in the first quarter, followed by a 2.5% decline in the second quarter, aligning with expectations. Performance varied significantly across regions.
The Americas region saw a solid recovery with revenue up 4.8% in the second quarter, reflecting normalization at the Raleigh industrial site in North America. The Europe, Middle East, and Africa (EMEA) region reported nearly stable revenue at -0.7%. In contrast, Asia experienced a significant contraction in sales, down 14.0%, primarily due to market adjustments in China following healthcare spending reforms. Guerbet reiterated its financial targets for 2026, anticipating revenue to be stable or slightly down on a CER and like-for-like basis. The company expects a restated EBITDA margin of around 8%, which includes approximately €35 million in costs for the remediation plan at its Raleigh site. Free cash flow is projected to be between -€50 million and -€70 million, influenced by lower restated EBITDA, increased capital expenditures, and restructuring costs related to the Group's transformation plan. The company also announced a strengthening of its Executive Committee to accelerate this transformation.